Medicines and thyroid gland

Česká verzia

Authors: M. Tajtáková
Authors place of work: I. interná klinika Lekárskej fakulty UPJŠ a UN Košice, Slovenská republika, prednostka prof. MUDr. Ivica Lazúrová, CSc.
Published in the journal: Vnitř Lék 2012; 58(2): 140-144
Category: Reviews

Summary

From their primary pharmacological effect, many drugs may also affect the thyroid gland function or the results of thyroid function tests. In addition to the drugs with a known effect on thyroid gland, including thionamides, thyroid hormones, recombinant TSH, iodine, iodide, amiodarone, lithium and heparin, novel compounds, including tyrosin-kinase inhibitors, immunomodulators and cytokines also have adverse effects on the thyroid gland. Novel drugs are then associated with new types of adverse thyroid effects.

Key words:
drugs – thyroid gland dysfunction – tyrosine kinase inhibitors – immunomodulators – cytokines

Zdroje

1. Heufelder AE, Wiersinga WM. Störungen der Schilddrüsenfunktion: durch Amiodaron Pathogenese, Diagnostik and Therapie. Dtsch Arztebl 1999; 96: 34–41.

2. Harjai KJ, Licata AA. Amiodarone induced hyperthyroidism: a case series and brief review of literature. Pacing Clin Electrophysiol 1996; 19: 1548–1554.

3. Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23: 735–731.

4. Barbesino G. Drugs affecting thyroid function. Thyroid 2010; 20: 763–700.

5. Joe G, Shashank RJ. Drugs and thyroid. JAPI 2007; 55: 215–221.

6. Bocchetta A, Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemiol Ment Health 2006; 2: 23.

7. Cappelli C, Rotondi M, Pirola I et al. TSH-Lowering Effect of Metformin in Type 2 Diabetic Patients. Differences between euthyroid, untreated hypothyroid, and euthyroid on L-T₄ therapy patients. Diabetes Care 2009; 32: 1589–1590.

8. Morteza Taghavi S, Rokni H, Fatemi S. Metformin decreases thyreotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. Diab Vasc Dis Res 2011; 1: 47–48.

9. Kebebew E, Lindsay S, Clark OH et al. Results of rosiglitazone therapy in patients with thyreoglobulin-positive and radioiodine- negative advanced differentiated thyroid cancer. Thyroid 2009; 19: 953–956.

10. Antonelli A, Ferrari SM, Fallahi P et al. Cytokines (interferon γ and tumor necrosis fac-tor α)-induced nuclear factor-kB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism 2011; 60: 277–283.

11. Laji K, Rhidha R, John R et al. Abnormal serum free thyroid hormone levels due to heparin administration. Q J Med 2001; 94: 471–473.

12. Wu X, Schott M, Liu C et al. Statins decrease the aberrant HLA-DR expression on thyreocytes from patients with Hashimoto’s thyroiditis. Horm Metab Res 2008; 40: 838–841.

13. Gullu S, Emral R, Bastemir M et al. In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto’s thyroiditis. Eur J Endocrinol 2005; 153: 41–48.

14. Medical News Today. http://www.medicalnewstoday.com/. 2009.

15. Eker SS, Akkaya C, Ersoy C et al. Reversible escitalopram-induces hypothyroidism. Gen Hosp Psychiatry 2010; 32: 559.

16. Shinohara N, Takahashi M, Kamishima T et al. The incidence and mechanism of sunitinib--induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer 2011; 104: 241–247.

17. Torino F, Corsello SM, Longo R et al. Hypothyroidism related to tyrosinekinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009; 6: 219–228.

18. Makita N, Miyakawa M, Fujita T et al. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 2010; 20: 323–326.

19. Sherman SI. Thyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23: 713–722.

20. Rogiers A, Wolter P, Op de Beeck K et al. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid 2010; 20: 317–322.

21. Sato S, Muraishi K, Tani J et al. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanes patients with renal cell carcinoma. Endocr J 2010; 57: 873–880.

22. Sakurai K, Fukazawa H, Arihara Z et al. Sunitinib-induced thyreotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tohoku J Exp Med 2010; 222: 39–44.

23. Lio S. Thyroid function and sunitinib treatment. In: In Endocrine Abstracts ITC 2010; 207.

24. van Doorn L, Eskens FA, Visser TJ et al. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid 2011; 21: 197–202.

25. Faris JE, Moore AF, Daniels GH. Sunitinib (sutent)-induced thyreotoxicosis due to destructive thyroiditis: a case report. Thyroid 2007; 17: 1147–1149.

26. Mannavola D, Coco P, Vannucchi G et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007; 92: 3531–3534.

27. Choi EH, Kim WG, Kim EY et al. The effect of sunitinib on growth and proliferation of normal rat thyroid cell line, FRTL-5. In: Endocrine Abstracts ITC 2010: 207.

28. Wong E, Rosen LS, Mulay M et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007; 17: 351–355.

29. Abdulrahman RM, Verloop H, Hoftijzer H et al. Sorafenib-induced hypothyroidism is associated with increased typ 3 deiodination. J Clin Endocrinol Metab 2010; 95: 3758–3762.

30. Kim TD, Schwarz M, Nogai H et al. Thyroid dysfunction caused by second-generation tyrosinekinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 2010; 20: 1209–1214.

31. Wotherspoon F, Kajicek JP, Flanagan DE. Autoimmune thyroid disease following treatment of multiple sclerosis with Campath-1H. In: Endocrine Abstracts BES 2005; 9: 207.

32. Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-lH). J Clin Invest 2009; 119: 1852–1853.

33. Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275–2285.

34. Yu S, Fang Y, Sharav T et al. CD8+ T cells induce thyroid epithelial cell hyperplasia and fibrosis. J Immunol 2011; 186: 2655–2662.

35. Remicade side effect: Thyroid cancer. http://www.ehealthme.com/. 2011.